"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!

lah-MOE-trih-JEEN
Lamictal
Tablets: 25 mg, Tablets: 100 mg, Tablets: 150 mg, Tablets: 200 mg, Tablets, chewable dispersible: 2 mg, Tablets, chewable dispersible: 5 mg, Tablets, chewable dispersible: 25 mg
Class: Anticonvulsant

 Action Chemically unrelated to existing antiepileptic drugs (AEDs); precise mechanism(s) unknown. One proposed mechanism suggests inhibition of voltage-sensitive sodium channels, thereby stabilizing neuronal membranes which modulates presynaptic transmitter release of excitatory amino acids (eg, glutamate, aspartate).

 Indications

Epilepsy: Adjunctive therapy in the treatment of partial seizures in adults and as adjunctive therapy in the generalized seizures of Lennox-Gastaut syndrome in pediatric and adult patients. Conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing AED (EIAED).

May be useful in adults with generalized tonic-clonic, absence, atypical absence, and myoclonic seizures.

 Contraindications Standard considerations.

 Route/Dosage As add-on therapy

Lamotrigine Plus AED Regimen Containing Valproic Acid:

CHILDREN (2 to 12 yr): PO Wk 1 and 2: 0.15 mg/kg/day in 1 to 2 divided doses. Wk 3 and 4: 0.3 mg/kg/day in 1 to 2 divided doses. Maintenance dose: 1 to 5 mg/kg/day (max 200 mg/day in 1 to 2 divided doses).

ADULTS (> 12 yr): PO Wk 1 and 2: 25 mg every other day. Wk 3 and 4: 25 mg once a day. Maintenance dose: 100 to 400 mg/day in 1 to 2 divided doses. To achieve, escalate dose by 25 to 50 mg/day q 1 to 2 wk.

Lamotrigine Plus EIAEDs without Valproic Acid:

CHILDREN (2 to 12 yr): PO Wk 1 and 2: 0.6 mg/kg/day in 2 divided doses. Wk 3 and 4: 1.2 mg/kg/day in 2 divided doses. Maintenance dose: 5 to 15 mg/kg/day (max 400 mg/day in 2 divided doses).

ADULTS (> 12 yr): PO Wk 1 and 2: 50 mg/day. Wk 3 and 4: 100 mg/day in 2 divided doses. Maintenance dose: 300 to 500 mg/day in 2 divided doses. To achieve, escalate dose by 100 mg/day q wk.

Patients receiving multi-drug regimens employing EIAEDs without valproic acid can have a maintenance dose of lamotrigine as high as 700 mg/day. With valproic acid, maintenance doses as high as 200 mg/day have been used. Patients receiving valproic acid and lamotrigine as a 2-drug regimen only cannot be given a safe and effective dose.

 Interactions

Acetaminophen, Carbamazepine, Primidone, Phenobarbital, Phenytoin, and Valproic Acid: May affect lamotrigine concentration.

Carbamazepine, Folate Inhibitors, and Valproic Acid: May be affected by lamotrigine.

 Lab Test Interferences None well documented.

 Adverse Reactions

CNS: Dizziness; ataxia; somnolence; tremor; depression; anxiety; headache; insomnia; convulsions; irritability; incoordination. DERMATOLOGIC: Rash (can be life threatening); pruritis; sweating. GI: Nausea; vomiting; diarrhea; dyspepsia; constipation; abdominal pain; anorexia. GU: Dysmenorrhea; vaginitis; amenorrhea; urinary tract infection. RESPIRATORY: Rhinitis; pharyngitis; bronchitis; pneumonia. OTHER: Flu syndrome; fever; neck pain; diplopia; blurred vision.

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy in children < 16 yr not established for uses other than the above listing. Melanin-Containing Tissues: Lamotrigine binds to melanin and may cause toxicity with possibility of long-term ophthalmologic effects. Special Risk Patients: Use with caution in renal/hepatic/cardiac function impairment. Photosensitivity: Photoallergy or phototoxicity may occur. Withdrawal Seizures: AEDs should not be abruptly discontinued because of possibility of increasing seizure frequency. Taper dose over a 2-week period. Rash: Serious rash such as Stevens-Johnson syndrome may occur; contact health care provider immediately. Renal Function Impairment: If significant impairment, reduce maintenance doses. Discontinuation Strategy: Administer a stepwise reduction of dose (50%/wk) over a 2-wk period. Discontinuing an EIAED may prolong the half-life of lamotrigine; discontinuing valproic acid may shorten the half-life of lamotrigine.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

  • Administer as prescribed.
  • May be administered without regard to meals.
  • Administer tablets whole. Chewing tablets may leave a bitter taste.
  • Chewable, dispersable tablets may be administered by chewing, swallowing whole, or dispersing in water or diluted fruit juice. Whole tablets, not fractions of tablets, must be administered.
  • To disperse chewable, dispersable tablets, add prescribed number of tablets to a small amount (1 tsp or enough to cover tablets) of water or diluted fruit juice. Wait about 1 min for tablet to disperse, then swirl solution; administer immediately. Do not attempt to administer partial quantities of the dispersed tablets.
  • Dosing regimen is dependent on age of patient, condition being treated, and concurrent use of other antiepileptic drugs.
  • Administer reduced dose to patients with liver or kidney impairment.
  • Store at controlled room temperature. Protect from moisture.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of kidney, liver, or cardiac function impairment.
  • Ensure that patient has reviewed the Patient Information before starting therapy.
  • Monitor patient for skin rash, fever, hives, sores in the mouth or around the eyes, and lymphadenopathy. Discontinue therapy and notify health care provider immediately if noted.
  • Monitor patient for GI, CNS, and general body side effects. Report to health care provider if noted and significant.
  • Implement safety precautions for patients who experience dizziness or ataxia.

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Instruct patient to take exactly as prescribed and to not change the dose or discontinue unless advised to do so by health care provider.
  • Advise patient to swallow tablet whole. Chewing the tablets may leave a bitter taste.
  • Instruct patient in proper use of chewable, dispersable tablets.
  • Advise patient that each dose may be taken without regard to meals.
  • Warn patient that if a dose is missed to not double up on the next dose.
  • Advise patient that if medication needs to be discontinued, it will be slowly withdrawn over a 2-wk period unless safety concerns (eg, rash) require a more rapid withdrawal.
  • Caution patient that drug may cause dizziness or drowsiness and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
  • Advise female patients to contact health care provider if becoming pregnant, planning on becoming pregnant, or breastfeeding.
  • Instruct patient to discontinue therapy and contact health care provider immediately if developing a skin rash, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, or swelling of the lips or tongue.
  • Instruct patient to contact health care provider if seizures get worse or if new types of seizures occur.
  • Advise patient to contact health care provider if developing side effects.
  • Advise patient to not take any prescription or otc medications or dietary supplements unless advised to do so by health care provider.
  • Advise patient that laboratory tests and follow-up visits will be required to monitor therapy and to keep appointments.

Popularity: 3% [?]


If you're still unable to find appropriate information in the article, please use search form below